Ads
related to: boston scientific stock price target
Search results
Results From The WOW.Com Content Network
The stock of Boston Scientific (NYSE:BSX, 30-year Financials) gives every indication of being fairly valued, according to GuruFocus Value calculation.
Boston Scientific acquired Target Therapeutics in a tax-free stock swap for about $1.1 billion, more than 10 times Target's total sales, in contrast to the usual multiple of 10 times earnings. [ 14 ] The Taxus Stent was approved in 2003 in Europe and other countries and, in the United States, by the FDA in March 2004.
Price Action: BSX stock is down 1.66% at $83.16 at last check Wednesday. Read Next: CDW Shares Dip As Q3 Sales Miss Amid Weak Hardware Demand And Customer Delays
For premium support please call: 800-290-4726 more ways to reach us
Boston Scientific: Guidant: 24.6 38 With the lower re-negotiated a lower price of $21.5 billion between Johnson & Johnson and Guidant, Boston Scientific announced an unsolicited offer of $24.6 billion for Guidant (an offer of $72 per share of Guidant, $36 in cash and a fixed number of Boston Scientific shares valued at $36 a share). 26 2006
For premium support please call: 800-290-4726 more ways to reach us
On December 5, 2005, Boston Scientific made a surprise unsolicited $24.6 billion bid to acquire Guidant, offering $72 per share of Guidant, $36 in cash and a fixed number of Boston Scientific shares valued at $36 a share. Guidant's stock price rose 10% on the news.
A global medical technology company, Boston Scientific (S&P 500: BSX), is focused on transforming lives through innovative medical solutions to improve the health of patients globally. Accretive ...